- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07631858
Perspectives About Online Information
June 2, 2026 updated by: NYU Langone Health
The purpose of this research study is to understand the perspectives of U.S. adults on online information about prostate cancer.
Study participants will receive different online information about prostate cancer to view such as a video post or text post, and complete a one-time online survey that will take approximately 10 minutes.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
3200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Nataliya Byrne
- Phone Number: 646-501-2681
- Email: Nataliya.byrne@nyulangone.org
Study Contact Backup
- Name: Stacy Loeb, MD, MSc, PhD
- Phone Number: 646-825-6300
- Email: Stacy.loeb@nyulangone.org
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- U.S. adult age 40+ who identifies as Black and/or Hispanic
- Enrolled in Dynata online survey panel
- Willing and able to participate in the research study.
Exclusion Criteria:
- Individuals up to age 39
- Individuals living outside the U.S.
- Individuals who are not Black and/or Hispanic
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Prostate Cancer Post with Video
Participants will receive a survey and be asked their perspective after reviewing a prostate cancer post with video
|
Participants will review a post about prostate cancer.
The survey will include questions about demographics and internet use.
It may also provide participants with resources about online information.
|
|
Experimental: Prostate Cancer Post without Video
Participants will receive a survey and be asked their perspective after reviewing a prostate cancer post without video.
|
The survey will include questions about demographics and internet use.
It may also provide participants with resources about online information.
Participants will review a post about prostate cancer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Trust in the post, as measured by a 4-point Likert scale
Time Frame: Post-intervention (~5 minutes)
|
A single question is asked of "How much do you trust the information in the post?"
Participants used a 4-point Likert scale from 1 (trust the information completely) to 4 (Did not trust the information).
Scores range from 1-4, with higher scores indicating less trust.
|
Post-intervention (~5 minutes)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Short-form Positive and Negative Affect Schedule (PANAS) Positive Score
Time Frame: Post-intervention (~5 minutes)
|
The Short-form Positive and Negative Affect Schedule (PANAS-SF) is a brief, 10-item psychometric tool used to assess two distinct emotional dimensions: Positive Affect (e.g., active, inspired) and Negative Affect (e.g., upset, afraid).
Respondents rate each of the 10 adjectives on a 5-point Likert scale.
Scores can range from 10 - 50, with higher scores representing higher levels of positive affect.
|
Post-intervention (~5 minutes)
|
|
Short-form Positive and Negative Affect Schedule (PANAS) Negative Score
Time Frame: Post-intervention (~5 minutes)
|
The Short-form Positive and Negative Affect Schedule (PANAS-SF) is a brief, 10-item psychometric tool used to assess two distinct emotional dimensions: Positive Affect (e.g., active, inspired) and Negative Affect (e.g., upset, afraid).
Respondents rate each of the 10 adjectives on a 5-point Likert scale.
Scores can range from 10 - 50, with lower scores representing lower levels of negative affect.
|
Post-intervention (~5 minutes)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Stacy Loeb, MD, MSc, PhD, NYU Langone Health
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2026
Primary Completion (Estimated)
January 31, 2028
Study Completion (Estimated)
January 31, 2028
Study Registration Dates
First Submitted
June 2, 2026
First Submitted That Met QC Criteria
June 2, 2026
First Posted (Actual)
June 8, 2026
Study Record Updates
Last Update Posted (Actual)
June 8, 2026
Last Update Submitted That Met QC Criteria
June 2, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Prostatic Neoplasms
- Health Care Quality, Access, and Evaluation
- Investigative Techniques
- Epidemiologic Methods
- Data Collection
- Health Care Evaluation Mechanisms
- Quality of Health Care
- Public Health
- Environment and Public Health
- Technology, Industry, and Agriculture
- Technology
- Tape Recording
- Audiovisual Aids
- Educational Technology
- Television
- Surveys and Questionnaires
- Videotape Recording
Other Study ID Numbers
- 25-01456
- 1R01CA278997 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health.
This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB).
Requests should be directed to: stacy.loeb@nyulangone.org.
The protocol and statistical analysis plan will be posted on Clinicaltrials.gov
only as required by federal regulation or supporting awards and agreements.
IPD Sharing Time Frame
Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
IPD Sharing Access Criteria
The investigator who proposed to use the data after signing a data use agreement will be granted access upon reasonable request for biomedical research purposes.
Requests should be directed to stacy.loeb@nyulangone.org.
To gain access, data requestors will need to sign a data access agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Cancer Institute and Hospital, Chinese Academy...RecruitingProstate Cancer Castration-resistant Prostate CancerChina
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Washington University School of MedicineThe Society of Nuclear Medicine and Molecular ImagingNot yet recruitingRecurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Prostate Cancer Recurrent | Prostate Cancer MetastaticUnited States
Clinical Trials on Post (video) about prostate cancer
-
University of Michigan Rogel Cancer CenterGenomeDx Biosciences Corp; Michigan Urological Surgery Improvement Collaborative...Completed
-
David SiegelICF Macro, Inc.Completed
-
Emory UniversityCompletedProstate CancerUnited States
-
The University of Hong KongTung Wah Group of HospitalsCompleted
-
University of CopenhagenUnknown
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedStage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate CancerUnited States
-
Georgetown UniversityU.S. Army Medical Research and Development CommandCompleted
-
University of Illinois at ChicagoCompletedLung Cancer ScreeningUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityThe First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaboratorsRecruiting
-
European Institute of OncologyAzienda Ospedaliera Universitaria Integrata Verona; Azienda Socio Sanitaria...Recruiting